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Summary The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by
inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is
inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb
cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical
cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical
epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA
level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization.
However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical
carcinoma cell lines, similar high levels of p16expression were seen. Point mutations or homozygous deletions of p16were not observed in
the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur
during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent
of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions
during the carcinogenesis of HPV-initiated cervical cancers.
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Eukaryotic cell division is regulated by a series of protein kinase
complexes consisting of cycin-dependent kinase (cdk) catalytic
units and cyclin control units (Liu et al, 1995; reviewed in Kamb,
1995; Weinberg, 1995). Furthermore, several cyclin-dependent
kinase inhibitors have been identified as the control system that
prevents the progression of the cell cycle. Examples are p21WAFI
(El-Deiry et al, 1993; Gu et al, 1993; Xiong et al, 1993; Noda et al,
1994), p27 (Polyak et al, 1994; Toyoshiba and Hunter, 1994), p15
(Hannon and Beach, 1994) and p18 (Guan et al, 1994). The deregu-
lation ofthe cell cycle was proposed as an important mechanism for
the malignant transformation of normal cells (Pardee, 1989). For
several kinds of cancers, the contribution of mutations in the
sequences ofthepl6 (M7TS) tumour-suppressor gene to the process
of the carcinogenesis was proposed. Then, a number of studies
showed that point mutations and homozygous deletions ofp16 for
some types ofcancers and cancer cell lines were frequent (Caldas et
al, 1994; Guan etal, 1994; reviewed inKamb, 1995; Liu etal, 1995).
However, alterations ofp16 were reported to be rare events in some
cancers and tumour cell lines (Beltinger et al, 1995; Liu et al, 1995;
Quesnel et al, 1995), including cervical carcinomas and cell lines
(Kelley et al, 1995; Hirama et al, 1996). Therefore, the significance
ofp16 in the evolution ofcervical cancer remains uncertain.
Received 19 June 1996
Revised24 September 1996
Accepted26 November 1996
Correspondence to: A Pater
*Present address: Department of Obstetrics and Gynecology, Saga Medical
School, Saga 849, Japan
Cervical cancer is the mostfrequent cancerofthe female genital
tract. Cervical carcinogenesis has been studied extensively by
various approaches, which firmly established the significance of
infections by the oncogenic human papillomaviruses (HPVs) as
initiators for the early stages (zur Hausen, 1994; zur Hausen and
de Villiers, 1994). The role played by promoting cofactor(s) in the
later steps ofprogression to cervical malignancy following initia-
tion remains uncertain, although many candidates are proposed
(Herrington, 1995).
Previously, we developed in vitro model systems for cervical
cancer. The systems were derived from: the human ectocervix that
supports infection; the endocervical origin of most cancers
(Tsutsumi et al, 1992); cells immortalized by HPV 16 and 18 that
resemble premalignant lesions (Tsutsumi et al, 1992; Yokoyama et
al, 1994); immortalized cells adapted to serum that are propagated
using the culture conditions used for cervical carcinoma cells
(Nakao et al, 1996); and cells malignantly transformed by treat-
ment with cigarette smoke condensate (CSC), an HPV co-factor
(Yang et al, 1996a; Nakao et al, 1996). The four stages of malig-
nant progression were proposed to represent the in vivo equiva-
lents in the multistep carcinogenesis of cervical cancer. In this
report, we examined the RNA, protein and DNA of the important
cellularp16 gene for the effects on transformation in our in vitro
systems. For comparison, the status ofp16 was assessed in biop-
sies of normal tissues, premalignant lesions and tumours from
the cervix.
MM Pater passed away on 2 November 1994.
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Table 1 Description of cells and cell lines
Cells HPVa Serumb Tumorigenicityc
HEN - - NT
HEC - - NT
HEN-16 16 - -
HEN-16S 16 + -
HEN-16T 16 + +
HEN-16-2 16 - -
HEN-16-2S 16 + -
HEN-16-2T 16 + +
HEC-18-1 18 - -
HEC-18-1S 18 + -
HEC-18-1CT 18 + +
CaSki 16 + +
HeLa 18 + +
C33A - + +
aHPV type with (-) indicating none. bAdapted to growth in medium with serum
(+) or serum-free medium (-). cTumorigenicity in nude mice was examined.
NT, not tested.
MATERIALS AND METHODS
Cells and cell culture
The cells used in this study are described in Table 1. One series of
the stages of carcinogenesis was represented by primary human
ectocervical cells (HEC), HPV 18-immortalized HEC (HEC-18-1),
serum-adapted HEC-18-1 (HEC-18-1S) and CSC-transformed
HEC-18-1 (HEC-18-ICT). The series was established and
cultured as described previously (Nakao et al, 1996). Primary
human endocervical cells (HEN), HPV 16-immortalized HEN
(HEN-16) and another type ofHPV 16-immortalized HEN (HEN-
16-2) were established and cultured as described previously
(Tsutsumi et al, 1992). Fetal calf serum-adapted HEN-16 (HEN-
16S) and HEN-16-2 (HEN-16-2S) were initiated and cultured as
described previously for HEC-18-1S (Nakao et al, 1996). All three
types ofserum-adapted.cells were non-tumorigenic on nude mice.
Malignantly transformed HEN-16 (HEN-16T) and HEN-16-2
(HEN-16-2T) were established and cultured as described previ-
ously (Yang et al, 1996a). The established cervical carcinoma cell
lines, CaSki, HeLa and C33A, were cultured with the same condi-
tions as the tumorigenic immortalized cells. For serum-adapted
cells immortalized by HPV 16 and the corresponding malig-
nantly transformed cell lines, the medium was supplemented with
100 ng ml-1 EGF and 0.4 gg ml-1 hydrocortisone.
Clinical samples
Paraffin-embedded tissue biopsies of various pathological lesions
ofthe cervix were from the SirMortimer B Davis-Jewish Hospital,
Montreal, Canada, and from T Wright and R Richart for invasive
adenocarcinomas of the endocervix. Samples were examined for
the presence of HPV DNA in DNA extracted by a previously
described method (Koffa et al, 1995). HPV-negative samples were
tested for the integrity of the DNA by polymerase chain reaction
(PCR) analysis of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) DNA. Based on the results, 14 samples were selected
for further studies of p16. The HPV type and the pathological
diagnosis ofeach sample are shown in Table 2.
Table 2 List of clinical samples, HPV type and pathological diagnosis















HPV negative. bNSPA, no specific pathological alteration. cHGSIL, high-
grade squamous intraepithelial lesion. dSCC, squamous cell carcinoma.
Northern blot RNA analysis
Total cellular RNA was prepared and analysed using Northern blot
assays as described previously (Yang et al, 1996b). The probe for
the complete p16 cDNA was randomly labelled with [32P]dCTP.
The actin probe was used as a control for the amount of RNA
loaded and efficiency ofblot transfer.
Polymerase chain reaction-single-strand conformation
polymorphism (PCR-SSCP) analysis of p16 DNA
To test for sequence alterations ofp16, PCR-SSCP analysis was
used with DNA from the cells and samples shown in Tables 1 and
2. The three primer pairs are described in Table 3 and were
designed previously (Zhang et al, 1994). One pair is for the
analysis ofp16 exon 1 and the other two pairs are for partly over-
lapping regions of most of exon 2. Two paraffin-embedded 8-gm
slices were extracted as described previously (Koffa et al, 1995).
Genomic DNA (50 ng) was amplified in the presence of I jCi
[33P]dCTP (New England Nuclear). PCR was as follows: 94°C for
2 min; 40 cycles of94°C for 1 min and 62°C for 1 min; 72°C for 1
min; and 6 min at 72°C. PCR-amplified DNA was resolved in 6%
polyacrylamide sequencing gels at 4°C. The gels were dried
without fixation and exposed to Kodak XAR film for 12-72 h. The
PCR amplification was repeated twice or more, and the results
were consistent.
HPV typing
The PCR non-radioactive HPV detection system used HPV LI
open reading frame consensus primers as described previously
(Yoshikawa et al, 1991) with some modifications. The system was
designed for highly sensitive and reliable screening and typing of
HPVs contained in clinical samples. This system can identify a
minimum of nine genital HPV types, HPV 6, 11, 16, 18, 31, 33,
42, 52 and 58. Amplification of 50 ng of DNA from paraffin-
embedded tissue was as follows: 94°C for 2 min; 40 cycles of
94°C for 1 min, 48°C for 1 min and 72°C for 2 min; and 6 min at
72°C. Electrophoresis of amplified DNA was in 1.5-3% agarose
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Table 3 Sequence and experimental design of primers
Sequence Experimental design
p16 El -sense, 5'-GCTGCGGAGAGGGGGAGAGCAGGCA-3' SSCPa for exon 1
p16 El -antisense, 5'-GCGCTACCTGATTCCMTTC-3' SSCP for exon 1
p16 E2-1-sense, 5'-ACAAGCTTCCTTTCCGTCATGCCG-3' SSCP for exon 2-1
p16 E2-1-antisense, 5'-CCAGGCATCGCGCACGTCCA-3' SSCP for exon 2-1
pl6 E2-2-sense, 5'-TTCCTGGACACGCTGGTGGT-3' SSCP for exon 2-2
p16 E2-2-antisense, 5'-TCTGAGCTTTGGAAGCTCTCAG-3' SSCP for exon 2-2
HPV Li-sense, 5'-CGTAAACGTTTTCCCTAT T -3' HPV screening
HPV Li-antisense, 5'-TACCCAAATACTCTGTATTG-3' HPV screening
GAPDH-sense, 5'-AGTACGCTGCAGGGCCTCACTCCTT-3' Control for DNA quality
GAPDH-antisense, 5'-AAGAGCCAGTCTCTGGCCCCAGCCA-3' Control for DNA quality
aSSCP, single-strand conformation polymorphism.
gels. Positive samples were examined by restriction enzyme
analysis to identify the HPV type. PCr analyses were repeated
twice or more and were consistent. ForHPV-negative samples, the
integrity ofthe DNA was tested by PCR analysis for GAPDH as a
control, using the same conditions as forp16.
Western blot analysis
Protein was extracted from approximately 107 growing cells by
lysis in 1 ml of 0°C extraction buffer (50 mM Tris-HCl, pH 8.0,
150 mm sodium chloride, 0.02% sodium azide, 1% NP-40, 0.1%
sodium dodecyl sulphate (SDS), 0.5% sodium deoxycholate and
10 ,ug ml-' aprotinin) for 30 min and centrifuging at 12 000 g for
10 min at 40C. The DC protein assay kit (Bio-Rad) was used to
quantify the protein. Ten micrograms of protein were fractionated
by electrophoresis in 15% SDS-polyacrylamide gels according to
standard protocols. Stained protein markers (Amersham) were
included in each gel as molecular weight standards. The proteins
were subsequently transferred to Hybond enhanced chemilumin-
escence (ECL) nitrocellulose membrane under semi-dry condi-
tions. For this non-radioactive analysis method, immunodetection
of p16 polyclonal antibody (C-20) (Santa Cruz) at 1:100 dilution
was performed using the ECL system (Amersham) according to
the manufacturer's instructions.
RESULTS
Expression of p16 RNA in in vitro model of cervical
carcinogenesis
Our in vitro model systems were used to examine the level oftran-
scriptional expression ofp16 in four stages of malignant progres-
sion by Northern blot analysis for the first 11 cell types listed in
Table 1. Representing the first stage were the human primary
endocervical cells, HEN. The second stage comprised two lines of
HPV 16-immortalized human endocervical cell lines, HEN-16 and
HEN-16-2. Third, these lines were used to produce the serum-
adapted non-tumorigenic cells, HEN-16S and HEN-16-2S. The
fourth and final stage was represented by the tumorigenic clones,
HEN-16T and HEN-16-2T. The analogous stages were repre-
sented by the following: primary human ectocervical cells, HEC;
one line of HPV 18-immortalized cells, HEC-18-1; the serum-
adapted non-tumorigenic derivative cells, HEC-18-IS; and the
tumorigenic counterpart cells, HEC-18-ICT. These cells of the
model systems were compared with three cell lines of established
human cervical cancer cells: CaSki containing HPV 16, HeLa
containing HPV 18 and C33A containing no HPV.
In Northern blot analysis, the transcriptional expression ofp16
was undetectable in primary HEN (Figure lA) and very low in
HEC (Figure iB). The RNA level was dramatically enhanced
following immortalization by HPV. The up-regulation was
observed irrespective of the type of HPV. Further, the results were
qualitatively similar for both HEN-16- and HEN-16-2-immortal-
ized HEN lines, representing the second stage in progression to
malignancy. Serum-adapted but non-tumorigenic HPV-immortal-
ized cells were used for the next stage in progression, as adaptation
to serum is correlated with the expression ofgrowth-related genes
(Rossi and Hirschhorn, 1991). In addition, the cells served as
controls for the effect of the growth conditions used in generating
and propagating the tumorigenic cells representing the final fourth
stage in malignant progression. Relative to the actin control, no
effects of serum selection were seen. More importantly, tumori-
genic cells malignantly transformed by the HPV cofactor in
cervical carcinogenesis, CSC, were examined. Compared with the
other two stages of HPV-immortalized cells, they showed no
significant alteration in the level oftranscription. Again, this result
applied to the three lines, both HPVs and two different cervical
cell types. To test the relevance to naturally occurring cervical
cancer, the established cervical carcinoma cell lines C33A, CaSki
and HeLa were examined. All three showed the same high expres-
sion level ofthep16 tumour-suppressor gene as the three stages of
HPV-immortalized cells. These levels were much higher than for
HEC and HEN (Figure lA and B).
Level of p16 protein in in vitro model
To test the possible effect of post-transcriptional or translational
regulation ofp16, we used Western blot analysis with same model
systems for malignant progression. The expression pattern of p16
protein was consistent with the results of mRNA expression. In
comparison with the HEN human primary endocervical cells
(Figure 2A) and HEC ectocervical parental cells (Figure 2B), the
expression ofp16 was enhanced in the HPV 16- and 18-immortal-
ized cells. The level ofexpression was stable during the final three
steps of carcinogenesis of the HPV-immortalized cells, regardless
of the changes that occurred during serum adaptation and tumori-
genesis (Yang et al, 1996a; Nakao et al, 1996). The three lines of
established cervical cancer cells showed high expression levels of
p16, protein levels consistent with those of our experimental
model systems (Figure 2).
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Figure 2 Level of p16 protein in in vitro model for oncogenesis. Western blot
analysis is for 10 gg of protein. Cells labelled above the lanes are described
in the text. Protein marker in kDa is indicated on the left
Figure 1 Transcriptional expression of p16 in vitro model for cervical
oncogenesis. Northern blot analysis of 20 gg of total RNA is shown. Cells
labelled above the lanes are,described in the text. The actin (Actin) probe,
used as a control for the amount of RNA loaded and efficiency of blot
transfer, is indicated. The size markers in kb are indicated on the left.
Point mutations and homozygous deletions in p16for
model for oncogenesis
To determine whether mutations ofp16 were involved in the three
steps of transformation of our cultured cervical cells, PCR-SSCP
analysis for band shifting was performed. One set of primers for
exon 1 and two sets for exon 2 ofp16 (Table 3) were used in three
separate analyses. However, no differences in the pattern of bands
were revealed by shifts for the HEN-16-series, HEN-16-2-series
and HEC-18-series in vitro models for cervical carcinogenesis.
Exon 1 and exon 2-1 primers revealed no changes in band patterns
(data not shown). Typically, the same result was shown by exon
2-2 (Figure 3). All the cell lines showed a pattern that was iden-
tical to those of the parental primary endo- and ectocervical cells,
HEN and HEC. Also, none had the complete loss of signals that
would indicate homozygous deletions. The results among the
HPV-positive HeLa and CaSki and HPV-negative C33A cervical
carcinoma cell lines were consistent with our model and with
previous reports (Figure 3; Kelley et al, 1995; Hirama et al, 1996).
Point mutations in cervical samples
To assess the relevance to the in vivo condition of the results with
our in vitro model systems, we examined 14 clinical specimens of
normal cervical tissues, high-grade squamous intraepithelial
lesions (HGSIL), squamous cell carcinomas (SCC) or invasive
adenocarcinomas (Table 2). PCR-SSCP was performed with the
same conditions that were used for the in vitro cultures. For each
of the three primer pairs, all 14 examined samples had the signals
of exon 1 and two portions of exon 2 ofp16. No changes in the
band patterns were apparently caused by sequence alterations of
p16 amplified from the DNA ofthe different tissues. The identical
patterns were seen, irrespective ofthe pathological status, the HPV
status and the sample (Table 2), as shown by the exon 2-1 result
(Figure 4, data not shown).
DISCUSSION
The pi6 gene product inhibits the progression of the cell cycle
through G, by binding to cdk4/6. Thereby, the phosphorylation of
the retinoblastoma gene (Rb) protein (pRb) by the cdks is
prevented. Consequently, pRb binds to and depletes the level of
the E2F transcription factor required for the expression of the
S-phase oncogenes that activate cell cycling. Therefore, the loss of
functional pJ6 disrupts the pattern of cellular gene expression and
initiates carcinogenesis through the deregulation of the cell cycle
(Kamb et al, 1994). Other recent information also indicates that
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Figure 3 Point mutations in p16for model for oncogenesis. PCR-SSCP analysis of DNA of p16exon 2 using exon 2-2 primers is shown. The water (H20)
control for contamination is indicated. Cells labelled above the lanes are described in the text
Normal HGSIL
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Figure 4 Point mutations in cervical samples. PCR-SSCP analysis of DNA of p16 exon 2 using exon 2-1 primers is shown. The HPV 16 (16), HPV 18 (18) or
absence of HPV (-) is indicated below the lanes. Other labels are described in the text
p16 functions as a negative regulator of the cell cycle in the pres-
ence of wild-type Rb through the pl6/cdk-cyclin/Rb cascade
(Guan et al, 1994; Lukas et al, 1995). In cells containing an inacti-
vated Rb or harbouring specific DNA tumour viruses, E2F is not
sequestered by Rb, resulting in uncontrolled cell growth (Aagaard
et al, 1995; Whitaker et al, 1995; Yeager et al, 1995). Furthermore,
wild-type pRb down-regulated the promoter ofp16, whereas the
negative feedback by low levels of p16 enhanced p16 expression
in Rb-inactivated, HPV-positive cells (Li et al, 1994). Recently,
the expression of p16 was found to be inversely correlated with
pRb and Bcl-2 in cancer cell lines and cancers (Otterson et al,
1994; Nakamura et al, 1996; Sakaguchi et al, 1996). For example,
the C33A used in this study have no functional Rb. The results
with p16 indicate the importance ofp16 to the in vivo condition.
The overexpression of p16 was observed in HPV-positive cell
lines and cell lines expressing mutant Rb (Tam et al, 1994;
Aagaard et al, 1995). Although it would be of further interest to
test p16 expression in cervical tumour, these data are consistent
with the hypothesis that pl6 expression and function are depen-
dent on Rb.
In cervical carcinogenesis, most cancers contain oncogenic
HPV DNA (Bosch et al, 1995). In vitro, the expression of viral E7
was necessary for transformation (von Knebel-Doeberitz et al,
1988). E7 binds and inactivates pRb. The introduction of HPV
during cervical cancer development apparently acted on the
pl6/cdk-cyclin/Rb cascade by inactivating pRb, the p16 down-
stream alternate target. However, it was unknown whether changes
during tumorigenesis were involved. Our in vitro model systems
suggest that the inactivation of pRb by HPV E7 occurred in the
initial immortalization step of oncogenesis. Consistently, no
changes in levels ofHPV mRNA were found during tumorigenesis
in these systems previously (Nakao et al, 1996; Sarma et al, 1996).-
No changes in expression level or genetic alterations ofpl6 were
suggested to be involved in tumorigenesis after immortalization.
This hypothesis is consistent with previous reports that genetic
alterations of p16 were rarely seen in HPV-harbouring cervical
carcinoma cell lines and HPV-negative cell lines that contain
mutant Rb (Kelley et al, 1995; Hirama et al, 1996).
Our in vitro model systems represent four stages of cervical
cancer: first, normal primary human endo- and ectocervical cells
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representing metaplastic and normal cervical tissues respectively.
Next, the HPV 16- or HPV 18-immortalized human cervical cells
and serum-adapted cells represent the continuum ofprogression to
high-grade squamous intraepithelial lesions (HGSILs). Finally, the
malignantly transformed cells represent cervical tumours. The
advantages ofthese systems in investigating multistep carcinogen-
esis are: (1) the origins of the immortalized cells are clearly
defined and distinct - each cell line was clearly endocervical or
ectocervical in origin (Tsutsumi et al, 1992; Sun et al, 1993;
Yokoyama et al, 1994); (2) immortalized cells were derived with
the two HPVs most frequently associated with the initiation of
cervical oncogenesis (zur Hausen, 1994); (3) malignant clones
were derived by treatment with CSC - cigarette smoking was
proposed as an environmental cofactor ofHPV, based on epidemi-
ological and molecular biological studies (Herrington, 1995).
Therefore the transformation of HPV-immortalized cervical cells
by CSC is relevant to the in vivo situation and provides a suitable
in vitro model for cervical cancer (Sarma et al, 1996; Yang et al,
1996a, b); and (4) the clinical lesions are relevant for the reasons
stated below. Previously, we reported differential oncogenic
potentials for our model systems with the in vitro organotypic
(raft) culture and in vivo implantation differentiation systems.
HPV-immortalized endocervical cells reconstructed into HGSIL-
like lesions, and HPV-immortalized ectocervical cells showed
low-grade SIL (LGSIL)-like lesions in the two differentiation
systems. Cells malignantly transformed by CSC resembled
HGSIL-invasive squamous cell carcinomas in the in vitro differen-
tiation system and were tumorigenic on nude mice (Nakao et al,
1996; Yang et al, 1996a). These results show that HPV-immortal-
ized cells correspond to LGSIL-HGSILs (Sun et al, 1992;
Tsutsumi et al, 1992; Yokoyama et al, 1994; Nakao et al, 1996;
Yang et al, 1996a). Because of these four reasons above, our
systems are attractive for studying the progressive stages of
cervical cancer.
The role ofp16 as a tumour-suppressor gene remains controver-
sial at present. Tumour-suppressor genes can act in early or late
stages of carcinoma development (reviewed by Vogelstein and
Kinzler, 1993). The roles of HPV E6 and E7 in inactivation of
p53 and pRb tumour suppressors are required but not sufficient.
For example, p53 deletions are seen in both HPV-positive and
-negative cervical cancer (Mullokandov et al, 1996). Thus, the role
ofpRb in senescence control may not have been its only role. Our
experiments support the previous finding that mutations of p16
infrequently disrupt the pl6/cdk-cyclin/Rb cascade for the trans-
formation that leads to cervical cancer (Kelley et al, 1995; Hirama
et al, 1996). Enhanced expression of p16 was observed in the
initial immortalization step by HPV. Furthermore, our studies in
the in vitro systems indicated that no inactivation of the pl6/cdk-
cyclin/Rb cascade occurs during the serum adaptation and tumori-
genesis of HPV-immortalized cells. This cascade was apparently
inactivated by the introduction of HPV but was insufficient for
progression to the malignant transformation stage. Consistently,
previous results suggested that p16 did not contribute to tumori-
genesis, as alterations of this gene were already present in non-
tumorigenic immortalized breast epithelial cells (Cairms et al,
1994; Spruck et al, 1994; Brenner and Aldaz, 1995).
In cytogenetic studies ofcervical cancer, high-frequency loss of
heterozygosity (LOH) and deletion of chromosomes 1, 3, 4, 5, 6,
10, 11, 17, 18 and X was reported (Sreekantaiah et al, 1988;
Yokota et al, 1989; Mitra et al, 1994). A recent small-scale study
found LOH of the 9p21 locus to which pl6 is mapped in 20% of
cervical cancer cases (Cairns et al, 1995). However, the short arm
of chromosome 9 or 9p2l have not been generally recognized as
'hot spots' forLOH. These findings are consistent with ourfinding
no mutations ofp16 in the in vitro model. Further, ourexamination
ofclinical samples was useful, although the number was relatively
limited and the possible contamination of some samples with
normal tissue surrounding the pathological lesions cannot be
excluded. However, our results were relevant in showing that
mutations of p16 are also infrequent events in clinical cervical
cancers.
Despite the absence ofp16 mutations in our immortalized cells
grown in vitro, RNA and protein levels were enhanced. Other
factors, such as mutations of splice sites and promoter sequences,
were shown to influence the level of other proteins in various
genetic diseases, including cancers (Friedman et al, 1994). Also,
events occurring downstream ofthep16 DNA may be involved in
the altered expression levels. Expression was unaltered following
tumorigenesis by CSC. Consistently, no published reports have
associated cancers that are promoted by smoke with the expression
ofp16. Apparently, the dysregulation of the cell cycle by p16 is
not the final step in progression to malignancy. Therefore, our
results showing increased levels of RNA and protein expression
following immortalization are important forclarifying the possible
mechanism of initiating events in the carcinogenesis of cervical
cancer. The fact that no increase was shown following the ultimate
tumorigenesis was also revealing.
In conclusion, we suggest that (a) genetic alterations ofp16 are
rare events in cervical carcinogenesis; (b) transcription ofp16 is
the level at which disruption of the pl6/cdk-cyclin/Rb cascade
occurs; (c) the disruption occurs during HPV-mediated immortal-
ization and HPV infection; (d) smoking is an additional cofactor
that acts by mutating the host genome, probably in p16-indepen-
dent mechanisms, although it is necessary for the full malignant
transformation that results in cervical epithelial neoplasms.
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